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The impact of treatment on progression of fibrosis in autoimmune hepatitis (AIH) is unknown. We
assessed the changes in liver fibrosis before and after treatment among these patients. Nineteen AIH
patients who had paired liver biopsies were studied. Of these, seven had been treated with 6 months
of cyclosporine A and the rest with 6 months of prednisolone for induction of remission. Thereafter
all had been maintained on azathioprine. Biopsy specimens before and after treatment were reviewed
by one pathologist and scored by the Ishak method. Mean fibrosis stages before and after treatment
were compared. Also, factors predicting significant fibrosis (stage ≥3) and cirrhosis (stage ≥5) at
presentation were assessed. Mean interval between biopsies was 3.38 years. Mean fibrosis stage
decreased from 4.53 to 2.16 following treatment (P < 0.001). Mean decrement in inflammatory
grade was 8 scores (range, 4–10) in patients in whom fibrosis improved, and 2 scores (range, 0–
4) in patients in whom fibrosis did not decrease after treatment (P < 0.001). ALT-to-platelet ratio
was the best predictor of significant fibrosis and also cirrhosis. Fibrosis commonly improves after
immunosuppressive treatment in AIH. ALT-to-platelet ratio can predict accurately the presence of
significant fibrosis and cirrhosis in AIH.
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Liver fibrosis is an important prognostic factor in chronic
liver diseases, as it gradually leads to cirrhosis. Most of
the complications of chronic liver diseases are due to ad-
vanced cirrhosis. It has been shown that effective treatment
of chronic hepatitis C affects progression of fibrosis favor-
ably (1). Additionally, regression of hepatic fibrosis after
treatment of the underlying cause has been reported in
secondary biliary fibrosis (2). Regression of liver fibrosis
in autoimmune hepatitis (AIH) has also been reported in
a recent study (3) and a few case reports (4, 5).
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The impact of treatment on the rate of progression of fi-
brosis in AIH is unknown. Additionally, factors associated
with liver fibrosis before treatment and factors associated
with regression of fibrosis after treatment in AIH have not
been addressed previously. The aim of this study was to
determine the fibrosis progression rate before and after
treatment in AIH, as well as to determine factors associ-
ated with liver fibrosis at presentation and those associated
with the absence of fibrosis after treatment.
MATERIALS AND METHODS
Data from patients with AIH who were treated at our center
between 1995 and 2002 were retrieved. AIH was diagnosed if the
patient had chronically elevated aminotransferases, hypergam-
maglobulinemia, positive auto-antibodies (antinuclear antibody,
anti-smooth muscle antibody, anti liver–kidney microsomal anti-
body type 2), histopathological features compatible with autoim-
mune hepatitis on liver biopsy, and absence of viral (hepatitis B
and C), metabolic (Wilson’s disease, α-1 antitrypsin deficiency,
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hemochromatosis), and drug-induced liver disease (including al-
cohol). Patients with AIH were included if they had paired pre-
and posttreatment liver biopsies. Liver biopsies were considered
adequate if there were at least four portal tracts per high-power
field. The study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki, and informed consent was ob-
tained from each patient before the study.
Nineteen patients were included. Seven patients were part
of an open-label cyclosporine trial in the treatment of autoim-
mune hepatitis (6). Five of these seven patients had been treated
initially with corticosteroids, however, they were switched to cy-
closporine because of intolerable side effects of corticosteroids.
Two of them were treated with cyclosporine at the start of treat-
ment. These seven patients were treated with cyclosporine A
(CSA; Neoral), 3 mg/kg body weight per day orally, for 6 months.
Dose adjustments were made to maintain the cyclosporine level
at 100–300 ng/ml. Then the treatment regimen was switched
to tapering off low-dose prednisone together with azathioprine,
and then azathioprine alone, 100 mg/day, was administered. The
other 12 patients were treated with prednisolone, 1 mg/kg body
weight for 3 months, then azathioprine, 100 mg/day, was added,
prednisolone was gradually discontinued, and azathioprine alone
was continued.
The following data were recorded: gender, age at first biopsy,
age at the time of initiation of disease (the time of occurrence
of the first symptoms ascribed to autoimmune hepatitis), and
body mass index (BMI). Serum alanine aminotransferase (ALT),
serum aspartate aminotransferase (AST), serum γ -globulin lev-
els, and platelet count at the time of the first and second liver
biopsies were also recorded.
Paired biopsy samples were reviewed by a pathologist blinded
to their sequence and to the clinical outcome of patients. The
biopsy specimens were stained with hematoxylin and eosin,
Masson’s trichrome, and reticulin and were scored using the
modified hepatitis activity index (7). Necroinflammation was
graded from 0 to 18. Fibrosis was staged from 0 to 6 (0, no fibro-
sis; 1–2, portal fibrotic expansion; 3–4, bridging fibrosis; 5–6,
cirrhosis).
Before treatment, the fibrosis progression rate (FPR) was cal-
culated by dividing the HAI fibrosis stage (each stage = 1 unit)
on pretreatment biopsy by the estimated duration of disease in
years. The FPR after treatment was calculated by dividing the
difference in fibrosis stage between the two biopsies (before and
after treatment) by the interval between the two biopsies in years.
Various clinical and laboratory factors (age, BMI, serum
γ -globulin, AST, ALT, platelet count, AST-to-platelet ratio, and
ALT-to-platelet ratio) were looked at for possible ability to pre-
dict liver fibrosis at presentation. AST-to-platelet ratio was cal-
culated using the following equation: [(AST/upper limit of nor-
mal of AST)/platelet count (×109/L)] × 100 previously used for
prediction of fibrosis in chronic hepatitis C (8). ALT-to-platelet
ratio was calculated in a similar manner. Finally, we tested which
variable was associated with absence of fibrosis (e.g., stage 0 or
1) after treatment. The following variables were assessed: serum
γ -globulin level of less than 4 g/dL at baseline, grading score of
more than 9 at the first liver biopsy, BMI of more than 27 (which
was the mean value), gender, age at first biopsy (younger than
40 years), duration of treatment, and type of medication used for
induction of remission.
Statistical Analysis. Data are reported as means and ranges.
Correlation of quantitative variables with fibrosis stage at pre-
sentation was assessed by the Spearman correlation coefficient.
TABLE 1. BASELINE CHARACTERISTICS OF THE STUDY PATIENTS
Factor
Age, mean ± SD 24.16 ± 14.78
Gender, males/females 5/14
BMI (kg/m2), mean ± SD 25.45 ± 5.36
Pretreatment stage 4.53 ± 1.35
Pretreatment grade 10.21 ± 2.57
Serum ALT (U/L), mean ± SD 724.06 ± 519.76
Paired t-test was used to compare variables before and after treat-
ment. Univariate analysis (χ 2 test and Mann–Whitney test) was
used to assess the association of different variables with the ab-
sence of posttreatment fibrosis. Logistic regression analysis was
then used to assess the independent association of various vari-
ables with the absence of fibrosis. P values less than 0.05 were
considered statistically significant. Statistical analyses were per-
formed using the SPSS, version 10.1, software package (SPSS,
Inc., Chicago, IL).
RESULTS
A total of 19 patients with AIH (5 men and 14 women)
were enrolled. Characteristics of the patients at base-
line are listed in Table 1. Mean duration of treatment
and mean interval between biopsies for all patients were
3.38 ± 2.28 years. Mean duration of treatment was 4.67 ±
2.13 years in the cyclosporine group and 2.63 ± 2.08 years
in the remaining patients (P = 0.06).
Mean serum AST decreased from 689.18 to 42.29 U/L
(P < 0.001); mean serum ALT decreased from 724.06 to
39.76 U/L (P < 0.001); and mean serum γ -globulin de-
creased from 4.34 to 1.46 g/dL (P < 0.001). Mean inflam-
mation grade decreased from 10.21 to 4.11 (P < 0.001).
Mean fibrosis stage decreased from 4.53 to 2.16 (P <
0.001). Mean FPR decreased from 5.87 to −0.72 U/year
(P < 0.001). There was a trend for more rapid fibrosis re-
gression after treatment in the cyclosporine group than in
the prednisolone group (FPR of −1.16 vs −0.46 U/year,
respectively; P = 0.06).
Fibrosis scores decreased by 2 to 6 points in 13 patients
(70%), remained unchanged in 5 (25%), and worsened
by 1 point in one (5%) patient. Fibrosis improved in all
seven patients treated with CSA. Of the 13 patients in
whom fibrosis decreased, 3 had a 2-point improvement,
and 10 had a 3-point improvement or more. In four of the
seven patients who had histologically confirmed cirrhosis
at baseline, fibrosis scores decreased to 0 or 1 at the follow-
up liver biopsy.
Mean interval between biopsies for patients in whom
fibrosis regressed was 4.2 years, while for those in whom
fibrosis did not regress this interval was 1.6 years (P =
0.003). Seven of 19 patients had interim liver biopsies. In
all of them the stages of interim biopsy specimens were
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TABLE 2. CORRELATION OF FACTORS WITH FIBROSIS STAGE AT
PRESENTATION
Factor Correlation coefficient P value
AST 0.62 0.009
ALT 0.65 0.004
Plt −0.63 0.005
AST-to-Plt ratio 0.64 0.017
ALT-to-Plt ratio 0.62 0.024
γ -Globulin −0.06 0.83
AST/ALT ratio 0.09 0.74
Age 0.27 0.26
Note. AST, serum aspartate aminotransferase; ALT, serum alanine
aminotransferase; Plt, platelet count.
between the first and the last biopsies (stages of interim
biopsies were lower than for the first corresponding biop-
sies and higher than for the last one).
Factors Associated with Advanced Fibrosis and
Cirrhosis at Presentation. Fibrosis stage at presentation
was significantly correlated with serum AST, serum ALT,
platelet counts, AST-to-platelet ratio, and ALT-to-platelet
ratio, but it was not associated with age, AST-to-ALT ra-
tio, serum γ -globulin and BMI (Table 2). Serum AST,
serum ALT, platelet count, AST-to-platelet ratio, and ALT-
to-platelet ratio were plotted against stage of fibrosis in
receiver operating characteristic (ROC) curves, and the
cutoff point best predicting significant fibrosis (stage ≥3)
and cirrhosis (stage ≥5) was determined (Tables 3 and 4).
The best predictor of significant fibrosis was an ALT-to-
platelet ratio ≥2.61 with an area under the curve of 100%
and 100% positive and negative predictive values. ALT-
to-platelet ratio ≥6.55 could predict cirrhosis with 100%
sensitivity and specificity (Tables 3 and 4, Figure 1).
Relationship Between Inflammation and Fibrosis
(HAI Grade and Stage). All 13 patients in whom fibrosis
had regressed showed at least two grades of improvement
in inflammation, while of the 6 patients with no change
or worsening of liver fibrosis, 3 had at least a two-grade
improvement in inflammation (100 vs 50%, respectively;
P = 0.02). Mean decrement in inflammatory grade was 8
scores (range: 4–10) in patients in whom fibrosis improved
and 2 scores (range: 0–4) in patients in whom fibrosis did
not decrease after treatment (P < 0.001).
TABLE 3. FACTORS PREDICTING SIGNIFICANT FIBROSIS (STAGE ≥3) AT PRESENTATION
Factor AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%)
AST ≥257 U/L 0.97 93.30 100 100 66.60
ALT ≥264 U/L 0.93 93.30 100 100 66.60
Plt ≤313,500/µL 0.75 100 50 94.10 100
AST-to-Plt ratio ≥2.5 0.93 93.30 100 100 66.60
ALT-to-Plt ratio ≥2.61 1 100 100 100 100
Note. AUC, Area under ROC curves; PPV, positive predictive value; NPV, negative predictive value;
AST, serum aspartate aminotransferase; ALT, serum alanine aminotransferase; Plt, platelet counts.
Factors Associated with Absence of Fibrosis After
Treatment. On univariate analysis longer duration of
treatment (≥3 years) and use of CSA were associated with
absence of fibrosis after treatment (P = 0.03 and 0.02, re-
spectively). On logistic regression analysis only the use of
CSA was associated with absence of fibrosis after treat-
ment (P = 0.045; 95% CI, 1.05–136.70).
DISCUSSION
Our data clearly show that liver fibrosis regresses with
treatment in AIH. In a recent report, Czaja et al. (3) showed
that prednisolone monotherapy led to an improvement of
liver fibrosis in AIH. In our series, AIH patients who re-
ceived induction therapy with either prednisolone or CSA
and maintained on azathioprine had regression of their
liver fibrosis.
Improvement in fibrosis scores was typically parallel to
reduction in inflammatory grading scores. This suggests
that liver inflammation is an important trigger for liver
fibrosis in AIH, and removing this inciting stimulus by
immunosuppressive treatment may lead to regression of
liver fibrosis. Sampling error is always a potential threat
in comparing paired liver biopsy specimens, but the par-
allel improvement in clinical and biochemical variables is
a reassurance that this is probably not the case in this in-
stance. Additionally, all liver biopsy samples had at least
four portal tracts and many of them had six or more por-
tal tracts. This also reduces the probability of sampling
errors.
We calculated the rate of fibrosis progression before
and after treatment. Our patients had a very rapid rate of
fibrosis progression before treatment. According to our
data these patients would have become cirrhotic within
less than 1.5 years of presentation if left untreated. This
should be interpreted with caution, as it is always diffi-
cult to determine when the disease has started. This is
because in many instances, appearance of symptoms is
not the beginning of the disease and the actual hepatic
fibro-inflammatory process may have started much ear-
lier than the first symptom (9). However, our data sug-
gest that patients with AIH who have high transaminase
Digestive Diseases and Sciences, Vol. 50, No. 3 (March 2005) 549
MOHAMADNEJAD ET AL.
TABLE 4. FACTORS PREDICTING CIRRHOSIS (STAGE ≥5) AT PRESENTATION
Factor AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%)
AST ≥515 U/L 0.82 90.90 83.30 90.9 83.3
ALT ≥503 U/L 0.83 90.9 83.3 90.9 83.3
Plt ≤206,000/µL 0.95 90.90 85.70 90.9 85.7
AST-to-Plt ratio ≥5.76 0.89 100 83.30 91.60 100
ALT-to-Plt ratio ≥6.55 1 100 100 100 100
Note. AUC, area under ROC curves; PPV, positive predictive value; NPV, negative predictive value;
AST, serum aspartate aminotransferase; ALT, serum alanine aminotransferase; Plt, platelet counts.
and high γ -globulin levels should be treated promptly fol-
lowing diagnosis. Since even a few months of delay in
the diagnosis or treatment after presentation can lead to
rapid progression to advanced fibrosis and cirrhosis. Rate
of fibrosis regression with treatment was also relatively
high (−0.70 U/year), especially in the cyclosporine group
(−1.16 U/year). This means that in the latter group, fi-
brosis regressed approximately one stage per year with
treatment. Our data suggest that in AIH patients with ad-
vanced fibrosis, performing posttreatment liver biopsies to
look for histologic remission is probably better postponed
for years after clinical and biochemical remission.
We found that use of CSA and longer duration of treat-
ment are associated with absence of fibrosis after treat-
ment. On logistic regression analysis, only use of CSA
was associated with absence of fibrosis after treatment,
albeit with a rather wide confidence interval (due to our
relatively small sample size). Some points should be kept
in mind while interpreting these data: This beneficial effect
may be due either to the longer duration of treatment in the
cyclosporine group than in those treated with prednisolone
Fig 1. ROC curves of ALT-to-platelet ratio in the prediction of cirrhosis
in the studied patients. An AUC of 1.0 is characteristic of an ideal test.
(4.67 vs 2.63 years, respectively; P = 0.06) or to different
mechanisms of immunosuppression of CSA and its pos-
sible antifibrotic effects (10, 11). Therefore, although this
is encouraging information about the potential long-term
benefits of induction of remission with CSA, it awaits con-
firmation in larger studies. Currently a head-to-head trial
comparing CSA and prednisolone for induction of remis-
sion in AIH is ongoing at our center.
We also found that ALT-to-platelet ratio is a useful
noninvasive marker of liver fibrosis in AIH. Since liver
fibrosis is correlated significantly with an increase in ALT
level and a decrease in platelet count, ALT-to-platelet ra-
tio can amplify the difference in ALT and platelet values
among patients with different stages of fibrosis (8). This
awaits prospective confirmation in another set of patients
with AIH. In addition, if the above index proves useful
for prediction of fibrosis in posttreatment liver biopsies, it
may be useful for follow-up of these patients and predic-
tion of the time of posttreatment liver biopsy.
Another limitation of our study (and any other study
using the modified HAI score) is that ordinal numerical
scores are used to describe a continuous variable (i.e., fi-
brosis). When using this system, it should be kept in mind
that progression from one stage to another does not neces-
sarily represent an ordinal progression in matrix accumu-
lation (12). An added limitation in any fibrosis reversibil-
ity study is the fact that with the Ishak staging system,
once a biopsy is stage 6, the histology can only remain
stable or improve. It cannot get worse. Hence, stability or
regression is expectable in cirrhotic patients.
In conclusion, liver fibrosis in AIH clearly regresses
after treatment; and a 6-month course of CSA for induc-
ing remission in AIH may have beneficial antifibrotic ef-
fects. ALT-to-platelet ratio seems to be a good noninvasive
marker of liver fibrosis in AIH. All these findings await
further careful testing in future studies.
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